A Clinical Study to Assess a Compression Device in Patients With Venous Leg Ulcers

NCT02561013 | Withdrawn

• 1 other identifier: 05-013293
• Study Type: interventional
• Target: N/A
• Locations: 2 countries
• Sites: 5

Brief Summary

The purpose of this study is to evaluate the product performance of a new adjustable compression system for the treatment of venous leg ulcers.

Conditions

Varicose Ulcer

Outcome Measures

Primary Outcomes (1)

• The primary efficacy endpoint is the number of ulcers achieving complete closure (100% epithelialization) after 12 weeks

  12 weeks

Secondary Outcomes (5)

• Wound area reduction and relative wound area reduction at weeks 4, 8, and 12.

  Up to 12 weeks

• Relative wound area reduction >/= 40% at Week 4

  4 weeks

• Time to complete closure

  1-12 weeks

• Occurrence of treatment-related adverse events

  0-12 weeks

• Occurrence of treatment-related drop-outs

  0-12 weeks

Study Arms (2)

3M™ Coban™ Custom Fit Compression System

EXPERIMENTAL

3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.

Device: 3M™ Coban™ Custom Fit Compression System

Profore

ACTIVE COMPARATOR

Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers

Device: Profore

Interventions

3M™ Coban™ Custom Fit Compression System DEVICE

3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve. The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together.

Also known as: Coban Fit Compression System

3M™ Coban™ Custom Fit Compression System

Profore DEVICE

PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.

Profore

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is the subject 21 years or older?
• Does the subject have an active venous leg ulceration? If multiple ulcers are present, the investigator will need to select a single ulcer of the study leg that is \> 2cm apart from any other ulcer?
• Does the subject have an ulcer size between 1cm2 and 12cm2?
• Does the subject have an ABPI between 0.8 and 1.3 that was taken within the past 28 days?
• Is the subject ambulatory?
• Is the subject or family member willing to self-manage the venous leg ulcer therapy at home in collaboration with the medical staff, including the ability to properly readjust the closure straps as indicated by tension indicators, and apply new dressings when needed?
• Is the subject able to understand questionnaire items and action items (e.g., Subject Diary)?
• Is the subject willing to give written informed consent, including permission to take photographs of the study leg?

You may not qualify if:

• Does the subject have severe arterial occlusive disease?
• Does the subject have decompensated heart insufficiency NYHA Class IV, ACC.AHA Stage D?
• Does the subject have septic phlebitis?
• Does the subject have severe deep vein thrombosis (phlegmasia cerulea dolens) and other conditions contraindicated according to established guidelines and local procedures?
• Does the subject have known hypersensitivity to any of the component materials?
• Does the subject have a suspected clinical infection of the ulcer or any other systemic infection (requiring antibiotics)?
• Does the subject have a suspected or confirmed cancerous ulceration?
• Does the subject have severe peripheral sensitive neuropathy?
• Is the subject participating in any other prospective study interfering with this study?
• Does the subject have any medical condition which in the professional opinion of the investigator disqualifies the subject from enrollment into the study?
• Does the subject have a history of noncompliance to therapies?

Sponsors & Collaborators

• 3M: lead

Study Sites (5)

Institute for Advanced Wound Care

Montgomery, Alabama, 36111, United States

Location

HealthEast Care System

Saint Paul, Minnesota, 55102, United States

Location

Jobst Vascular Institute

Toledo, Ohio, 43606, United States

Location

Lawson Health Research Institute

London, Ontario, N6C 0A7, Canada

Location

Calea Ltd

Mississauga, Ontario, L4W 4Y3, Canada

Location

MeSH Terms

Conditions

Varicose Ulcer

Condition Hierarchy (Ancestors)

Varicose Veins; Vascular Diseases; Cardiovascular Diseases; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Patrick J Parks, MD, PhD

  3M Critical & Chronic Care Division

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2015
• First Posted: September 25, 2015
• Study Start: September 1, 2015
• Primary Completion: March 1, 2016
• Study Completion: March 1, 2016
• Last Updated: November 25, 2015

Record last verified: 2015-11

Locations

CA (2); US (3)